IO Biotech, Inc. (IOBT)
(Delayed Data from NSDQ)
$0.90 USD
+0.05 (6.41%)
Updated Sep 9, 2024 04:00 PM ET
After-Market: $0.90 0.00 (0.21%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth A Momentum C VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
IOBT 0.90 +0.05(6.41%)
Will IOBT be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for IOBT based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for IOBT
IO Biotech (IOBT) Down Despite Positive Update on Melanoma Study
IOBT: What are Zacks experts saying now?
Zacks Private Portfolio Services
Other News for IOBT
Analysts Offer Insights on Healthcare Companies: BioMarin Pharmaceutical (BMRN) and IO Biotech (IOBT)
Nasdaq Dips Over 2%; US Construction Spending Falls In July
IO Biotech price target lowered by $3 at Morgan Stanley, here's why
IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA? (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma
IO Biotech says IDMC recommends continuation of IO102-IO103 trial